Pharmaceutical leaders implement Model N to improve margins and mitigate risk, as surveys highlight growing urgency in responding to global pricing pressures.
REDWOOD SHORES, CA – April 7, 2014 – Model N, Inc. (NYSE: MODN) Model N Rainmaker 2014 key segments will focus on the semiconductor industry to address industry pricing, buyer-seller information flow, and rising R&D and manufacturing costs.
Eleven leaders in the semiconductor industry will speak at Rainmaker 2014, the 10th annual Model N Revenue Management Summit for technology companies, which will take place in Savannah, Georgia, April 23-24, 2014.
TJ Rodgers, CEO, Cypress Semiconductor, and Jim Camp, CEO, NegotiatorPro, will explore how manufacturers can take a more professional, scientific and analytical approach to deal negotiation, abandon age-old concepts around the importance of relationships and how buying decisions are always based purely on logic. End-customer expectations for continued ASP decline are sharply contrasted by rising costs of R&D and manufacturing. Semiconductor and component manufactures need to start resetting those expectations.
Ron Jones, CEO, N-Able Group, and George Stelling, co-founder of MarginXL Capital Partners and former CIO of NVidia, will chair two panel discussions on the role of sales team in demand creation, in an industry in which end-customers typically dictate both design and volume. Panelists include leaders from Microchip, PMC, Atmel, CSR and NXP.
Additional expert panel discussions will pursue this theme and look at how sales can add value when customers have all the information they need and how sales intelligence can influence business performance.
“This summit will highlight the growing consensus in the semiconductor industry that they can no longer support their customers’ expectation that prices will continue to drop every year,” says Chanan Greenberg, senior director, strategic markets, Model N.
“With R&D costs and manufacturing costs rising, accelerated ASP erosion will directly hit margin. As a result, companies have to find new ways to ensure volume agreements are met and stand their ground when negotiating contracts and prices.”
About Model N
Model N is the leader in Revenue Management solutions. Model N helps its customers maximize their revenue and reduce revenue compliance risk by managing every dollar that impacts their top line encompassing contracting, pricing, incentives, and rebates. Model N leverages its deep industry expertise to support the unique business needs of Life Sciences and Technology companies in more than 50 countries. Global Customers include: Actavis, Allergan, Amgen, Atmel, Boston Scientific, Bristol-Myers Squibb, Dell, Johnson & Johnson, Linear Technology, Merck, Marvell, Maxim, Micron, Nokia, Novartis, Novo Nordisk, ON Semiconductor, and STMicroelectronics. Learn more at: www.modeln.com. Model N is traded on the New York Stock Exchange under the symbol MODN.
Model N® is the registered trademark of Model N, Inc. Any other company names mentioned are the property of their respective owners and are mentioned for identification purposes only.